The largest database of trusted experimental protocols

Minimed

Manufactured by Medtronic
Sourced in United States

The MiniMed is a compact and portable lab equipment designed for various laboratory applications. It serves as a reliable and versatile tool for researchers and technicians in various scientific fields.

Automatically generated - may contain errors

17 protocols using minimed

1

Continuous Glucose Monitoring and Oxidative Stress

Check if the same lab product or an alternative is used in the 5 most similar protocols
At subject study entry, a subcutaneous continuous glucose monitoring system (CGMS) sensor (Medtronic MiniMed®, Northridge CA, USA) was inserted subcutaneously into the abdominal region and calibrated.
Fingertip capillary blood glucose was measured at least three times per day and values were used to titrate CGM meters. The monitor was removed after three days, and data was downloaded and analyzed using CGMS Software version 3.0 (CA, USA). Eight to twelve hours fasting venous blood samples were collected on the Day 1 and 8 hours overnight urinary samples on Day 3 of this continuous interstitial glucose monitoring period. Collected blood samples were stored at −80°C until laboratory testing for analysis of oxidative stress biomarkers and other laboratory tests.
+ Open protocol
+ Expand
2

Continuous Glucose Monitoring in Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Continuous glucose monitors were used to record electrochemically measured subcutaneous interstitial glucose concentrations every 5 min, generating 288 measurements per day. Both studies used Medtronic CGM systems (MiniMed, Medtronic, Northridge, CA, USA), with CGM Gold sensors being used in the UK and Guardian REAL-Time CGM with Sof-sensors being used in Denmark. Monitors were calibrated against capillary blood glucose measurements as per the manufacturer’s instructions.
+ Open protocol
+ Expand
3

Inspiratory Muscle Exercise and Glycemic Control

Check if the same lab product or an alternative is used in the 5 most similar protocols
One subgroup of 6 patients with diabetes was randomly assigned to two sessions of inspiratory muscle exercise either with 2% of PImax (placebo condition) or 60% of PImax (metaboreflex activation), in different days with one week apart. Subjects were admitted to the laboratory in the morning, when the CGMS device was placed (Medtronic Mini-Med, Northridge, CA). The sensor was inserted through a needle into the subcutaneous tissue of the abdominal wall using a spring-loaded device (Senserted Medtronic, Northridge, USA) 24h before the beginning of the protocols and maintained through the exercise sessions until a 30 min of recovery after the sessions was reached, when it was removed. Glucose measurements were obtained every 10 s and averaged every 5 min, for a total of 288 readings per day. Sensor readings were calibrated with a glucose monitor (Accu-Check Performa, Roche Diagnostics, Mannheim, Germany) using 4 finger stick blood samples obtained over the 24-h period. Patients were previously instructed about the operation of the monitor. Subjects were asked to closely match their daily nutritional intake.
+ Open protocol
+ Expand
4

Observational Trial of Medtronic MiniMed

Check if the same lab product or an alternative is used in the 5 most similar protocols
This was an investigator-initiated observational trial. The Institutional Review Board of the Academic Medical Center (Amsterdam, The Netherlands) approved the study protocol (study ID: NL41498.018.12). Medtronic MiniMed provided three devices for the duration of the trial and the necessary sensors but had no influence on study design or study reporting. Patients or next of kin had to provide written informed consent before the start of any study-related procedure.
+ Open protocol
+ Expand
5

Continuous Glucose and Cardiac Monitoring Post-PCI

Check if the same lab product or an alternative is used in the 5 most similar protocols
All of the patients were equipped with CGMS (Medtronic Mini-Med, USA) and were monitored for 72 consecutive hours after p-PCI. A CGMS sensor was inserted in the abdominal subcutis and was calibrated every 6 h according to the manufacturer’s indications. blood glucose levels of each patient was examined by a self-monitoring of blood glucose (SMBG) device (Medisafe Mini, Terumo, Japan) at least 4 times per day. The sensor measures interstitial glucose every 10 s and records the mean values at 5-min intervals. The sensor remained in place for 3 days for the collection of data, having been adapted from previously established criteria for optimal accuracy of the CGMS [10 (link), 11 (link)].
Holter was used to monitor for cardiac ischemia and arrhythmia simultaneously. Continuous glucose and Holter monitoring was performed over a period of 72 h. The CGMS and Holter were removed after 72 h.
The Holter monitoring recordings were read by a cardiologist, and the glucose monitoring results were read by an endocrinologist, both of whom were blinded to the other’s results.
+ Open protocol
+ Expand
6

Pulsatile Subcutaneous Hydrocortisone Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols
A portable subcutaneous infusion pump (Crono P, CANE Applied Medical Technology Ltd, Cambridge, UK) containing 100 mg of hydrocortisone in 1 ml (efcortesol®; Soverign, Essex UK) was made up to 10 ml with 0·9% saline and preprogramed to deliver a high-, medium- and low-sized pulse of hydrocortisone. All pulses were delivered at a flow rate of 10 μl/s. The pump delivered hydrocortisone subcutaneously via a cannula (Medtronic quick-set®, Medtronic MiniMed, Northridge, CA, USA) inserted into the abdominal subcutaneous tissue.
+ Open protocol
+ Expand
7

Continuous Glucose Monitoring for 72 Hours

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients were equipped with a CGMS device (Medtronic miniMed, Northridge, CA, USA) and monitored for 72 h. Each CGMS device was calibrated with SMBG four times per day. After the 72 h monitoring period, all recorded data were downloaded onto a personal computer. Glucose profiles and glucose excursion parameters were evaluated with miniMedSolutions software version 3.0 (miniMed, Symar, CA, USA). Parameters analyzed included average, maximum and minimum BG concentrations, and the standard deviation of glucose concentration.
+ Open protocol
+ Expand
8

Continuous Glucose Monitoring in Gestational Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CGMS (Medtronic MiniMed) was used to monitor interstitial glucose every 5 min during the randomized diet assignments. Women were blinded to CGMS glucose concentrations. Identical glucometers were provided by the investigators (OneTouch, LifeScan Inc., Milpitas, CA); postprandial glucose was measured either 1 or 2 h after meals as per obstetrician preference, with the accepted targets of <140 mg/dL at 1 h and <120 mg/dL at 2 h (1 (link)). Preprandial glucose via glucometer four times daily was also measured for calibration of the CGMS sensor data (correlation between interstitial and meter glucose, r = 0.732; P < 0.0001; n = 840 measures). Women recorded meter glucose and meal start times. CGMS sensors were placed near the lateral iliac crest by an investigator. During the investigation, wireless CGMS equipment became available, but the sensor technology was unchanged. Given it was no longer possible with the wireless device to discern any sensor malfunction, women with the wireless CGMS monitors (n = 4) wore two sensors side-by-side, 1 inch apart in the same adipose tissue bed. The mean of interstitial glucose data from the two sensors was used for analysis in these cases. CGMS glucose variables were extracted and represent the mean over 48 h as we have described in detail previously (20 (link),21 (link)).
+ Open protocol
+ Expand
9

Continuous Glucose Monitoring in Islet Transplantation

Check if the same lab product or an alternative is used in the 5 most similar protocols
T1D subjects were evaluated using a 72-h continuous glucose monitoring system (CGMS) (Medtronic MiniMed) before and at 75 days after islet transplantation.
+ Open protocol
+ Expand
10

Continuous Glucose Monitoring for Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eligible patients who agreed to participate were monitored by a masked CGM (Medtronic MiniMed, Northridge, CA) for a 4-day period without a change in their diabetes regimen. Patients were encouraged to record 4 SMGB (capillary blood) levels each day to calibrate the CGM. They were instructed to follow their usual diet and were advised to abstain from intense and prolonged exercise during the 4-day period.
Glucose variability was expressed as SDBG, overall glucose CV%, MAGE, and MODD. SDBG was defined as the standard deviation of all readings during the CGM. CV% was calculated by the following formula: CV% = SDBG/mean blood glucose (MBG)∗100%. MAGE was defined as the average of absolute values of differences between adjacent peaks and nadirs for all differences >1 standard deviation (SD). MODD was calculated as the mean of the absolute values of the differences between any given glucose value and the value exactly (24 × d) hours later.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!